Advertisement

Editor Profile

Michael E. Williams, MD, ScM

Associate Editor

About the NEJM Watch Oncology and Hematology Board

Dr. Williams is the Byrd S. Leavell Professor of Medicine, Professor of Pathology, and Chief, Hematology/Oncology Division, University of Virginia School of Medicine, Charlottesville. Dr. Williams received his MD from the University of Cincinnati College of Medicine and a Master of Science from the Harvard University School of Public Health. He completed his Medicine residency, Chief Residency, and Fellowship in Hematology/Oncology at the University of Virginia Health System in Charlottesville, where he joined the faculty in 1986. His research interests are in the pathogenesis and therapy of non-Hodgkin lymphoma and chronic lymphocytic leukemia, and in targeted therapeutic approaches for hematologic malignancies. Dr. Williams serves on the Scientific Advisory Board of the Lymphoma Research Foundation, the ASCO Scientific Program Committee (Myeloma and Lymphoma) and is a member of the Scientific Advisory Board of the European Mantle Cell Lymphoma Network. He is Chair of the Hematology Subspecialty Board of the American Board of Internal Medicine, and participates regularly in regional and national programs devoted to education and research in lymphoma and other blood cancers. Dr. Williams has been writing for NEJM Journal Watch Oncology and Hematology since 2006.

Disclosures

Consultant / Advisory board

Celgene; Millennium; TG Therapeutics

Speaker's bureau

Research To Practice; ION; Xcenda

Grant / Research support

Celgene; Janssen; Allos; Genetech; Millennium; Pharmacyclics; Gilead; Bristol-Myers-Squibb; Cephalon

Editorial boards

American Board of Internal Medicine, Hematology; Current Treatment Options in Oncology

Summaries by Michael Williams

Pages